Over the past year, we have continued to see the negative correlation between the 10-Year and the XBI.
November was no different as you can see:
What else do you need to know? There is a lot going on to end the year and the JP Morgan Healthcare Conference is going to be another excellent one in January.
Obesity
Eli Lilly announces a new $3B capacity expansion investment in Wisconsin manufacturing facility in hopes of helping ramp up production of Zepbound to which demand has outpaced supply as analysts forecast the market for GLP-1 therapies will exceed $100B annually by 2030
Novo Holding’s pending $16.5B transaction of Catalent was granted “unconditional approval” by the European Commission clearing the way for a year-end 2024 close subject to the FTC decision.
Biden Administration proposes Medicare & Medicaid coverage for anti-obesity medications.
Managed Care
UnitedHealthcare receives a slight boost in 4+ STAR membership after a federal judge ruled in favor of the company’s lawsuit against the CMS citing that the agency unfairly assessed the insurer’s customer service call center scoring.
Humana announces a CFO transition with Susan Diamond replaced by Celeste Mellet, currently the finance chief at an investment fund, effective Jan 2025
The American Society of Hematology (ASH) Annual Meeting
Exciting progress updates from several players in the “off-the-shelf” CAR-T therapies, which do not require patient samples and are much faster and cheaper to manufacture than currently approved, patient-derived autologous therapies.
Data from the next generation of cell therapies for Sickle Cell Disease showed approved players in the space may have some competition coming, fueled by novel gene editing technologies that improve upon CRSPR.
Comments